Related Experiment Videos
Peroxisomal diseases
P M Palosaari1, J M Kilponen, J K Hiltunen
1Department of Medical Biochemistry, University of Oulu, Finland.
Insights
Peroxisomal diseases are rare metabolic disorders impacting well-being. Dietary fatty acid changes show promise in managing conditions like x-linked adrenoleukodystrophy (ALD).
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Peroxisomal diseases are rare inherited metabolic disorders with severe health consequences.
- Zellweger syndrome exemplifies generalized peroxisomal dysfunction.
- X-linked adrenoleukodystrophy (ALD) is the most common peroxisomal disease, characterized by neurological symptoms.
Purpose of the Study:
- To review the nature of peroxisomal diseases.
- To discuss diagnostic approaches.
- To highlight therapeutic advancements.
Main Methods:
- Diagnosis relies on clinical presentation and metabolite analysis (very long chain fatty acids, bile acid intermediates, plasmalogens).
Main Results:
- Dietary supplementation with long-chain monounsaturated fatty acids (erucic acid, oleic acid) and very long chain fatty acid restriction benefits ALD patients.
- Docosahexaenoate (C22:1) shows potential in some studies.
Conclusions:
- Peroxisomal diseases represent a significant challenge in metabolic medicine.
- Dietary interventions offer a promising avenue for managing specific peroxisomal disorders like ALD.
Abstract:
The peroxisomal diseases, which are rare inborn metabolic errors, often have serious effects on the well being of the individual and many of them are fatal at an early age. The Zellweger cerebro-hepato-renal syndrome represents a group consisting of diseases with a generalized loss of peroxisomal functions and is considered as a prototype for peroxisomal dysfunction. The largest group includes those diseases where only a single peroxisomal function is impaired. The most common peroxisomal disease, x-linked adrenoleukodystrophy (ADL), belongs to this group, and neurological symptoms dominate among the patients. The primary diagnosis is usually based on clinical findings and measurement of accumulated or depleted metabolites in the body (e.g. very long chain fatty acids, bile acid intermediates or plasmalogens). Some progress has been made in treating of the peroxisomal diseases. Many patients with x-linked ALD have benefitted from the supplementation of the diet with long chain monounsaturated fatty acids like erucic acid or oleic acid with the simultaneous restriction of very long chain fatty acids. Docosahexenoate (C22:1) has also shown promising results in some studies.